US Patent

US11857603 — PTH compounds with low peak-to-trough ratios

Method of Use · Assigned to Ascendis Pharma Bone Diseases AS · Expires 2037-09-28 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition of a PTH compound that has a specific pharmacokinetic profile after subcutaneous administration.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3982 — Yorvipath
U-3982 — Yorvipath
U-3982 — Yorvipath

Patent Metadata

Patent number
US11857603
Jurisdiction
US
Classification
Method of Use
Expires
2037-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Bone Diseases AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.